iShares Biotechnology ETF (IBB)

The Federal Reserve's recent 50bps rate cut could significantly boost biotech companies by lowering borrowing costs and improving access to capital.

The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150.

Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market.

ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors

The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout.

Gilead Sciences (NASDAQGILD) saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial.

The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs.

The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains

The iShares Biotechnology ETF (NASDAQIBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%.

Stocks finished in the green to close the week; investors believe the jobs report will allow the Fed to leave interest rates unchanged when they meet next week

If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.

The recent reversal and reclaim of the significant $124 support level in the IBB holds importance, indicating a potential shift in momentum.

As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming.

Moderna's value has declined by over 75% from its peak as the world moves on from the COVID-19 pandemic, leading to concerns about its investment appeal.

The current consolidation in the IBB signals a potential breakout might be looming as key moving averages have converged within a contracted price range.

IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQTARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Tarsus will be added to the NASDAQ Biotechnology Index® NASDAQ: NBINASDAQNBI)

The world of biotech is having what some are calling a golden age. Many companies are presenting new and innovative drugs to the FDA for approval and later the public for consumption. Smart Beta EFTs like SPDR S&P Biotech (NYSEXBI) (“XBI”) and iShares Biotechnology NASDAQ: IBBNASDAQIBB)

BlackRock, Inc. (NYSEBLK) today announced product enhancements to two iShares ETFs as part of an ongoing process to periodically review its product lineup.